Primary Care (Pediatrics and Family Practice) (Need Safer Effective) Primary Options For Depression and ADHD



Same
Ingredients
2 Brands



Can Keep Them "Happy For Life"

By Effectively Treating The Root Causes of Depression, Anxiety and ADHD Naturally and Safely



Clinical Dietary Management of Major Depressive Disorder

Once-a-day dosing / No age restriction

TEAM METHYLATION


PRE-METABOLIZED COENZYMES AND COFACTORS: BRAIN READY INGREDIENTS

Most Diverse Folates: FDA 15mg DFE L-Methylfolate Magnesium Folinic Acid. Dihydrofolate	2.5mg
B Vitamins in their Bioactive Coenzyme For B12 (Adenosylcobalamin). B6 (Pyridoxal-5-Phosphate). B1 (Thiamine Pyrophosphate). B2 (Flavin Adenine Dinucleotide). B3 (Nicotinamide Adenine Dinucleotide). Bioperine (B Vitamin Bioenhancer). Betaine (Trimethyl Glycine).	50mcg 25mcg 25mcg 25mcg 25mcg 25mcg
Minerals in their Bioactive Cofactor Form Magnesium Ascorbate Magnesium L-Threonate Zinc Ascorbate Iron (Ferrous Glycine Cysteinate)	1mg
Phospholipid Form-Brain Ready PS-Omega-3 (Phosphatidylserine, EPA, DHA)	23.3mg
Absorption Enhancer Sodium Citrate Energizer	10mg
CoQ10	500mcg

Methylation Chart

EnLyte/EnBrace HR provides all the down stream coenzymes, cofactors, and omegas needed to normalize and balance biochemical endpoints which correlates into clinical remissions in well controlled clinical trials.

EnLyte, EnBrace HR Product Ingredients Maroon | Biochemical End Points Green



THE JOURNAL OF

CLINICAL PSYCHIATRY


MAY 2016


Correlation of Clinical Response With Homocysteine Reduction During Therapy With EnLyte/EnBrace HR in Patients With MDD Who Are Positive for MTHFR C677T or A1298C Polymorphism

Andrew Farah, MD



OBJECTIVE: This study was designed to evaluate the efficacy and safety of EnLyte/EnBrace HR as monotherapy in adults with major depressive disorder (MDD) who were also positive for at least 1 methylenetetrahydrofolate reductase (MTHFR) polymorphism associated with depression and further test the hypothesis that EnLyte/EnBrace HR will lower homocysteine in a majority of clinical responding patients.





NO SIDE EFFECT WAS REPORTED AT GREATER RATE THAN PLACEBO

ONSET OF ACTION 2 WEEKS




EnBrace HR For The Treatment and Prevention of Depression in Women Trying to Conceive and During Pregnancy



Marlene P. Freeman, MD et al, Annals of Clinical Psychiatry February 2019 | FDA Approved

Relapse Prevention Group: MDD, But Well at Baseline Due to SSRIs/SNRIs, Drug ADs Replaced With EnBrace HR at Pregnancy




RESULTS:

Patients did not relapse to a major depressive episode or state compared to 63% that did in the Cohen Comparator.

CONCLUSION:

Study results suggest EnBrace HR is a novel and well tolerated intervention with efficacy for the prevention and treatment of depression among women planning pregnancy and who are pregnant.

Female Hormones Regulate Serotonin in The Female Brain! EnBrace HR normalizes and balances neurotransmitters in times of fluctuation and deficiency to treat:



Tension/Anxiety - Depressed Mood - Irritability/Anger - Appetite Changes - Cravings - Insomnia - Social Conflict Withdrawal -Feeling Overwhelmed - Hopelessness - Hot Flashes **Case Report**

A Clearly Needed ALL-NATURAL SAFE OPTION

IMedPub Journals http://www.imedpub.com

Clinical Psychiatry ISSN 2471-9854

Coenzyme Treatment of Childhood and Adolescent Depression and ADHD:

A Case Series

A. Farah MD, Gauri Madan MD, April 21, 2021

In Depression

- Indicated for MDD
- No Age Restriction
- Majority in Study Remitted
- No Side Effects Reported
- No Suicidal/Violent Thoughts

In ADHD

Treat "Adjunctively" with
Stimulants to Address the "Whole
Symptom Complex"

- Root Biochemical Cause
- Emotional Dysregulation
- Psychiatric Comorbidities
- Nutritional Deficiencies

"Monotherapy"

- Root Biochemical Cause
- In MTHFR SNP
- To Avoid Drug Side Effects
- During Drug Holiday

MDD Algorithm:

Andrew Farah MD, DFAPA

- 1. EnLyte 1 a day
- 2. Partial Goal, Week 3
 Add Prozac 5-10 mg. a day
- 3. Partial Goal, Week 6, Each BID

ADHD Step-Care Algorithm:

Arwen Podesta MD, DFAPA, DFASAM

- 1. EnLyte 1 a day
- 2. Partial Goal, Week 4
 Add Drug Non-Stimulant
 Or Low Dose Drug Stimulant
- 3. Partial Goal, Week 8
 Increase Drug Stimulant

ALLNATURAL SAFETY PROFILE

FDA Reported Side Effects	EnLyte	SSRI's	SNRI's
Weight Gain	No!	Yes	Yes
Loss of Libido, difficulty achieving erections, inability to reach orgasm	No!	Yes	Yes
Increased thoughts of suicide and aggression in adolescents & adults	No!	Yes	Yes
Drowsiness or Confusion	No!	Yes	Yes
Nervousness & Agitation	No!	Yes	Yes

Adapted from: Consumer Reports Best Buy Drugs. Using antidepressants to treat depression: comparing efficacy, safety and price. 2012

"90% of individuals with depression have lower serum/CNS folate levels than individuals without depression"

A. Bender et al, The Association of Folate and Depression A Meta Analysis, Journal of Psychiatric Research, 2017, 3470 Studies

CONTRIBUTORS TO FOLATE AND OTHER B VITAMIN COENZYME DEFICIENCIES

GENETIC	CONDITIONS	DRUGS	POPULATIONS	
MTHFR SNPS	Gastric Bypass	Lamictal	Pregnant	
C677T	Celiac Disease	Metformin	Post Partum	
A1298C	Kidney Disease	Methotrexate	Breast Feeding	
Known	Liver Disease	Corticosteriods	Elderly	
Suspected	Diabetes	NSAIDs	ADHD/ASD	
Family History	Cancers	Antibiotics	Hispanic	
Mental Illness	Anemias	Anticonvulsants	Alcoholic	
Miscarriages	Crohn's	Oral	Drug Addiction	
Birth Defects	Psoriasis	Contraceptives	Smokers	
Heart Disease	Eczema	Cholesterol	Child Bearing Age	
Diabetes	Infection	Lowering	Depression	
OTHER	Viral	Diuretics	Contaminants	
B-Vitamin	or	H2 Antagonists	Low Socio	
Non Tested	Bacterial	Phenytoin	Economic	
Methylation	Cardiac	SSRIs	Poor Nutrition	
Polymorphisms	Epilepsy	SNRIs	Vegetarian	
Suspected	Seizures	Aspirin	Stressed	





The only RX products that meet the ingredient requirements for the

American Psychiatric Association

Complementary and Alternative Medicine in Major Depressive Disorder: The American Psychiatric Association Task Force Assessment of Evidence, Challenges and Recommendations

APA Taskforce: Marlene Freeman MD, Maurizio Fava MD, J Lake MD, MH Trivedi MD, David Mischoulon MD

"Folate: Folate and several related compounds have received study to ascertain if there is a potential role in the treatment of MDD. There is consistent and growing evidence of a role for various folate forms in the prevention and treatment of depression. Studies to date demonstrate efficacy of augmentation of antidepressants with folic acid, folinic acid (leucovorin), and 5-methyltetrahydrofolate (5-MTHF). Similar findings may be attributable to the fact that these folate forms share an interconversion potential in the complex set of pathways that comprise the one-carbon or methylation cycles. These reactions, which in turn depend on B12 and homocysteine availability, are postulated to exert an antidepressant effect by impacting the synthesis of neurotransmitters such as serotonin, dopamine, and norepinephrine."

"Folate and methylfolate monotherapy may benefit certain depressed populations. Folate augmentation can also be used to enhance antidepressant efficacy from the start of treatment

or, for patients who are already on antidepressant

treatment, to convert partial or non-responders

into responders or remitters."

"We advocate, folate/methylfolate with B12 and Omega 3s as monotherapy or augmentation strategy for MDD."



MDD Algorithm:

Andrew Farah MD, DFAPA High Point University

Adult MDD/Mild – Moderate

- EnLyte/EnBrace HR 1 a day
- -Partial/non-response at 4 weeks, Enlyte/EnBrace HR twice a day
- -Partial/non-response add SRI or SNRI, continue EnLyte/EnBrace HR (BID)

Adult MDD/Severe

EnLyte/EnBrace HR with SRI or SNRI [from day 1]

Partial/non-response at 3 weeks – increase Enlyte/EnBrace HR to BID / increase dose of antidepressant @ clinician discretion

Partial/non-response 6 weeks - Enlyte/EnBrace HR BID/switch AD/or escalate dose at discretion

No response 12 weeks to BID Enlyte/EnBrace HR and >3

ADs: TMS or ketamine + Enlyte/EnBrace HR

MDD in Pregnancy:

EnLyte/EnBrace HR 1 a day

Partial/non-response - 3 weeks Enlyte/EnBrace HR BID

Partial/non-response 6 weeks- continue Enlyte/EnBrace HR, add SRI [Not Paxil/Wellbutrin]

Partial/non-response 9 weeks: cont. Enlyte/EnBrace HR with new AD or with TMS

References

- 1. Jain R. et al, Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD, CNS Spectrums, 2019
- 2. Bender A et al, The association of folate and depression: A meta-analysis, Journal of Psychiatric Research, 2017
- 3. Liwinski T et al, Folate and Its Significance in Depressive Disorders and Suicidality: A Comprehensive Narrative Review, Nutrients, 2023
- 4. Farah A et al, Coenzyme Treatment of Childhood and Adolescent Depression: A case Series, Clinical Psychiatry. 2021
- 5. Stahl S, L-Methylfolate: A Vitamin for Your Monoamines, Journal of Clinical Psychiatry, 2008
- 6. Stover P et al, Folate Nutrition and Blood-Brain Barrier Dysfunction, CurrO pin Biotechnol, 2017
- 7. Asbaghi et al, Effects of Folic Acid Supplementation on Inflammatory Markers, Nutrients, 2021
- 8. Orsolini L et al, C-Reactive Protein as a Biomarker for Major Depressive Disorder, IJ Molecular Sciences, 2022
- 9. Freeman M et al, Complementary and Alternative Medicine in MDD Recommendations, American Psychiatric Association, 2009
- 10. Jones P, Folate and Inflammation, Science Direct, 2019
- 11. Fava AM et al, Folate in Major Depressive Disorder, Journal of Clinical Psychiatry, 2009
- 12. Zhang Y et al, Association between variants of MTHFR genes and psychiatric disorders: A meta-analysis, Frontiers in Psychiatry, 2022
- 13. Farah A et al, A Case Series Addendum Addressing the ADHD Symptom Triad, Clinical Psychiatry, 2021
- 14. Freeman et al., A prenatal supplement with methylfolatefor the treatment and prevention of depression in women trying to conceive and during pregnancy, Annals of Clinical Psychiatry, Feb. 2019
- 15. Farah et.al, Correlation of Clinical Response with Homocysteine Reduction During Therapy With Reduced B Vitamins in Patients With MDD Who Are Positive for MTHFR C677T or A1298C Polymorphism, Journal of Clinical Psychiatry, May 2016
- 16. MRC Vitamin Group, Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study, Lancet, 1991
- 17. Czeizel et al., Periconceptional Folic Acid and Multivitamin Supplementation for the Prevention of Neural Tube Defects and Other Con-genital Abnormalities, Clinical and Molecular Teratology, 2008
- 18. FDA, 21 CFR-101.79-Health Claims: Folate and neural tube defects, CFR Text. 2019
- 19. Kirk E et al., Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study, BMJ, 2004
- 20. Ufriend et al., The C677T polymorphism of the methylenetetrahydrofolate reductase gene and idiopathic recurrent miscarriage, Obstetrics & Gynecology, April 2002
- 21. MTHFR Living, Preparing for Pregnancy with MTHFR Mutations, Jan. 2014
- 22. Garilli, Bianca ND, MTHFR Mutation: A Missing Piece in the Chronic Disease Puzzle, Huffington Post, Summer, 2012
- 23. Wald et al, Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake levelof folate,
- 24. Farah et al., The Prevalence and Role of MTHFR Polymorphism in Opiate Dependency, Journal of Addiction and Therapies, Feb.2018
- 25. El-Hadidy et al., Methylene tetra hydrofolatereductase C677T Gene Polymorphism in Heroin Dependence, Addiction Research & Therapy, 2015



- 27. Chambers et al., SSRI and Risk of Persistent Pulmonary Hypertension of the Newborn, The New England Journal of Medicine, 2011
- 28. Kieviet et al., Use of antidepressants during pregnancy in The Netherlands: observational study into post-partum interventions, BMC Pregnancy & Childbirth, 2017
- 29. MGH Center for Women's Health, womensmentalhealth.org, SSRlsand Poor Neonatal Adaptation: How Long do Symptoms Last, 2015
- 30. Liu et al., Antidepressant Use During Pregnancy and Psychiatric Disorders in Offspring, BMJ, 2017
- 31. Lugo-Candelas et al., Association Between Brain Structure and Connectivity in Infants and Exposure to SSRIsDuring Pregnancy, JAMA Pediatrics, 2018
- 32. WebMD. www.webmd.com, pregnancy-and-antidepressants, 2018
- 33. FDA AAppendix NIH, Antidepressant Drug Labels for Pregnant and Postpartum Women, 2014
- 34. EnBrace HR PI, FDS Daily Med, Dec. 2018
- 35. Turgal et al. MTHFR Polymorphisms and Pregnancy Outcome, PMC 6138472, Sept. 2018
- 36. Duprey Robert P. MTHFR Gene Polymorphism positive treatment-resistant depression, Neuropsychiatry 2019
- 37. ImbardA, Benoist JF, BlomHJ. Neural tube defects, folic acid and methylation. Int J Environ Res Public Health. 2013
- 38. Obeid R, HolzgreveW, PietrzikK. Is 5-methyltetrahydrofolate an alternative to folic acid for the prevention of neural tube defects? J. Perinatal Med, 2013
- 39. Greenberg JA, Bell SJ, Guan Y, Yu YH. Folic Acid supplementation and pregnancy: more than just neural tube defect prevention. Rev ObstetGynecol. 2011
- 40. NIH, Folate Fact Sheet for Professionals, 2022
- 41. MGH Center for Women's Mental Health, Folic Aid Supplements Before and After Conception: Prevention of Autism, 2022
- 42. BjorkM, Riedel B, SpigsetO, VeibyG, Kolstad E, DaltveitAK, GilhusNE. Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol. 2018 Feb
- 43. Sah AK, Shrestha N, Joshi P, LakhaR, Shrestha S, Sharma L, Chandra A, Singh N, Kc Y, RijalB. Association of parental methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism in couples with unexplained recurrent pregnancy loss. BMC Res Notes. 2018 Apr
- 44. MGH Center for Womens' Mental Health Folic Acid and Risk of Perinatal Depression: Is there an Association? 2012
- 45. Methylenetetrahydrofolate Reductase Polymorphisms and Pregnancy Outcomes, Obstetrics and Gynecology, 2018
- 46. Zhang L, Sun L, Wei T. Correlation between MTHFR gene polymorphism and homocysteine levels for prognosis in patients withpregnancy-induced hypertension. Am J TranslRes. 2021 Jul



Diane Pratt

National Sales Manager

Learn More At: www.EnlyteRX.com diane.pratt@enlyterx.com



HOW TO PRESCRIBE



USE OUR ONLINE PRESCRIBER FORM

Visit www.enlyterx.com and click on "Prescribe Now!"

Fill in prescriber and patient information and then hit "submit"

WE WILL OFFER YOUR PATIENT THEIR FIRST BOTTLE AT A DISCOUNTED PRICE OF \$29.95

We will also provide them with the insurance steps and help determine the most cost-effective option moving forward

IF IT'S COVERED ON INSURANCE, WE WILL CONTACT YOUR OFFICE WITH PRESCRIBING INFORMATION

If your patient does not have coverage or has a high co-pay, we will offer our discounted cash-pay option for EnLyte (ENL). No further action is needed from your office.

Insurance Coverage

MEDICAID COVERAGE

LOUISIANA: EnBrace HR / EnLyte Preferred on La MCD with no prior auth

TEXAS: EnLyte Preferred on Texas MCD with no prior auth

SOUTH DAKOTA: Enlyte is Preferred on SD MCD with no prior auth

Plus other state MCD plans

COMMERCIAL COVERAGE

COMMERCIAL COVERAGE IS DEPENDENT ON INDIVIDUAL INSURANCE PLANS

DISCOUNTED CASH PAY OPTION: If EnLyte is not covered on an individual insurance plan, patients have the option of purchasing the non-prescription version called "ENL" through Direct Value Dispense at an affordable cost.